Artificial intelligence-enabled discovery of a RIPK3 inhibitor with neuroprotective effects in an acute glaucoma mouse model.

Journal: Chinese medical journal
PMID: 39719694

Abstract

BACKGROUND: Retinal ganglion cell (RGC) death caused by acute ocular hypertension is an important characteristic of acute glaucoma. Receptor-interacting protein kinase 3 (RIPK3) that mediates necroptosis is a potential therapeutic target for RGC death. However, the current understanding of the targeting agents and mechanisms of RIPK3 in the treatment of glaucoma remains limited. Notably, artificial intelligence (AI) technologies have significantly advanced drug discovery. This study aimed to discover RIPK3 inhibitor with AI assistance.

Authors

  • Xing Tu
    Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong 510530, China.
  • Zixing Zou
    Institute for AI in Medicine and Faculty of Medicine, Macau University of Science and Technology, Macau, China; State Key Laboratory of Eye Health, Eye Hospital and Institute for Advanced Study on Eye Health and Diseases, Wenzhou Medical University, Wenzhou, China; National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, China; Guangzhou National Laboratory, Guangzhou, China.
  • Jiahui Li
    College of Communication Engineering, Jilin University, Changchun, Jilin China.
  • Simiao Zeng
    Department of Reproductive Medicine, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong 510623, China.
  • Zhengchao Luo
    Department of Big Data and Biomedical AI, College of Future Technology, Peking University, Beijing 100871, China.
  • Gen Li
    Department of Orthopedics, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai, 200072, P.R.China.
  • Yuanxu Gao
    Institute for AI in Medicine and Faculty of Medicine, Macau University of Science and Technology, Macau, China; State Key Laboratory of Eye Health, Eye Hospital and Institute for Advanced Study on Eye Health and Diseases, Wenzhou Medical University, Wenzhou, China; National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, China; Department of Big Data and Biomedical AI, College of Future Technology, Peking University and Peking-Tsinghua Center for Life Sciences, Beijing, China.
  • Kang Zhang
    Xifeng District People's Hospital, Qingyang, China.

Keywords

External Resources

Popular Topics
Recent Journals